Please login to the form below

Not currently logged in

Opdivo improves survival in oesophageal cancer

BMS releases new data from its phase 3 CHECKMATE-648 study

Bristol Myers Squibb

In interim results released yesterday, Bristol Myers Squibb's (BMS) Opdivo, a PD-(L)1 checkpoint inhibitor showed improved survival in oesophageal cancer from its phase 3 CHECKMATE-648 study.

Opdivo in combination with chemotherapy and a combination of Opdivo and Yervoy improved on chemotherapy alone in extending survival of patients with first-line oesophageal squamous cell carcinoma whose tumours are metastatic or can’t be surgically removed.

In data from the phase 3 CHECKMATE-648 study, a combination of Opdivo and chemotherapy showed an improvement over chemotherapy alone in reaching its primary overall survival (OS) and progression-free survival (PFS) endpoints in PD-(L)1-expressing tumours.

BMS said that while Opdivo plus Yervoy hit its OS primary endpoint, it missed the PFS co-primary endpoint.

These results for BMS’ PD-(L)1 checkpoint inhibitor show first-line efficacy across all upper GI tumour locations, including in the stomach, gastro-oesophageal junction and oesophagus.

The results from the phase 3 CHECKMATE-648 study support the results from the CHECKMATE-649 study, which tested Opdivo plus chemotherapy in first-line patients with advanced or metastatic gastric cancer, gastro-oesophageal junction cancer or oesophageal adenocarcinoma.

The US Food and Drug Administration (FDA) accepted a priority review for BMS’ Opdivo plus chemotherapy combination in stomach cancer earlier this year.

The US regulator will review the combination treatment for the first-line treatment of patients with advanced or metastatic gastric cancer, gastro-oesophageal junction cancer or oesophageal adenocarcinoma.

The FDA has set a prescription drug user fee act (PDUFA) goal date for a decision on BMS’ immunotherapy regimen of 25 May.

Article by
Iona Everson

12th April 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....